Davor Štimac, MD PhD is a graduate of the School of Medicine, University of Rijeka, Croatia. He is the Head of the Specialty Hospital Medico and full professor at School of Medicine, University Rijeka, Croatia. He is the former President of the Croatian Society of Gastroenterology, Croatian Pancreatic Club, vice president of Croatian Academy of Medical Sciences. He is a President of Croatian Society for Obesity. He is a member of the European Board of Gastroenterology, a member of the WGO Guidelines committee, a member of UEG General Assembly and a member of European Association for Gastroenterology,Endoscopy and Nutrition Council. His main scientific interests are focused on hepatic and pancreatic diseases and obesity. He has published more than 400 abstracts and articles in peer-reviewed journals.

Catherijne Knibbe is clinical pharmacologist-hospital pharmacist in the St. Antonius Hospital in Nieuwegein/Utrecht and professor of Individualized Drug Treatment at the LACDR, Faculty of Science at Leiden University. She leads the Quantitative Clinical Pharmacology group which focuses on the development and application of advanced computational techniques combining the statistical power of the Population approach with Physiologically-Based approaches, to predict the efficacy and safety of drugs and optimize dosing in special patient populations like such as (prematurely born) neonates or children, individuals with obesity or critically ill patients. In the St. Antonius hospital, Dr. Knibbe is consultant for the department of Intensive Care and Anesthesiology, is supervisor of the Clinical Pharmacology training program, is co-supervisor of the Hospital Pharmacy training program, and member of the Daily Board of the Department of Clinical Pharmacy of the St. Antonius hospital. She has supervised 28 PhD students and is co-author of over 280 international peer-reviewed publications and contributions to books. She is a frequently invited speaker on national and international conferences. Dr. Knibbe is an active member of the American College of Clinical Pharmacology (ACCP) where she became Fellow in 2019 and member of the Board of Regents in 2020.

Professor Dinko Vitezić, MD, PhD is a specialist in Clinical Pharmacology employed at the University of Rijeka School of Medicine Rijeka, and the University Hospital Centre Rijeka, Croatia. He is conducting undergraduate courses in Clinical Pharmacology and participates in courses which are part of postgraduate studies at the School of Medicine in Rijeka and at the University of Zagreb, School of Medicine and at the Faculty of Pharmacy and Biochemistry. Professor Vitezić is the author of publications in the field of clinical pharmacology and pharmacoeconomics in different medical journals and co-editor of a textbook Fundamentals of Clinical Pharmacology and Clinical Pharmacology (in Croatian), author of texts in the field of clinical pharmacology published in several textbooks (25 different chapters). He was invited speaker and a member and chairman on several international and national conferences and meetings. He is a president of the Croatian Society for Clinical Pharmacology and Therapeutics. He was and is involved in the drug regulatory field as an expert for drugs (Chairman of the Central Ethical Committee of the Republic of Croatia for clinical drug trials and the Drug Committee of the Ministry of Health and Croatian Agency for Medicinal Products and Medical Devices) Professor Vitezić is national counterpart for pharmaceutical strategy implemented (Pharmaceutical counterpart) for the World Health Organization and he was a member for a decade of the Committee for Orphan Medicinal Products of the European Medicines Agency.

Dr. Andrej Belančić is a (31 years old) Specialist in Clinical Pharmacology at the Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Croatia. He also holds the academic title of Lecturer at the Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Croatia. In 2024, he was awarded the title of Best Young Scientist at the Faculty of Medicine, University of Rijeka. Dr. Belančić is the author or co-author of approximately 100 scientific and professional full-text articles and about 200 scientific abstracts. He has contributed as an author or co-author to several national guidelines in the field of metabolic diseases, authored multiple book chapters, and served as editor for several books, textbooks, and manuals. His scientific activities primarily focus on clinical pharmacology (treatment outcomes, pharmacoeconomics, pharmacovigilance, clinical trials), obesity and associated metabolic diseases, and rare disease therapeutics. He serves as Co-chair of the Early Career Clinical Pharmacologists Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT) and is an active member of the Croatian Society for Clinical Pharmacology and Therapeutics of the Croatian Medical Association. He is also an active member of the European Society of Hypertension (ESH) Working Group on Diabetes and Metabolic Risk Factors, and the ESH Working Group on Lifestyle, Cardiovascular Therapy and Adherence. Dr. Belančić is a member of the Croatian Hypertension League, Secretary of the Croatian Society of Obesity of the Croatian Medical Association, and a member of the European Association for the Study of Obesity (EASO) and the World Obesity Federation (WOF). Furthermore, he is an active member of the Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association.

I'm currently pursuing a Ph.D. in Pharmacy at the University of Otago, New Zealand, with a research focus on personalized medicine and antiplatelet therapy. My clinical journey began in 2006 at Sultan Qaboos University Hospital in Oman, where I’ve worked as a clinical pharmacist for nearly two decades. I hold both a Bachelor’s and Master’s degree in Pharmacy from the University of Toledo, USA. My current research investigates clopidogrel responsiveness in Omani patients, a critical area given that clopidogrel remains the only P2Y12 inhibitor available in tertiary hospitals across Oman. I'm passionate about advancing individualized treatment strategies to improve cardiovascular outcomes in the region.